Afam Capital Boosted Its Mosaic (MOS) Stake; Fibrogen (FGEN) SI Decreased By 16.05%

November 14, 2017 - By Clifton Ray

Afam Capital Inc increased Mosaic (MOS) stake by 39.14% reported in 2017Q2 SEC filing. Afam Capital Inc acquired 45,534 shares as Mosaic (MOS)’s stock declined 29.59%. The Afam Capital Inc holds 161,882 shares with $3.70 million value, up from 116,348 last quarter. Mosaic now has $8.09B valuation. The stock declined 1.07% or $0.25 reaching $23.05 on the news. About 586,530 shares traded. Mosaic Co (NYSE:MOS) has declined 7.87% since November 14, 2016 and is downtrending. It has underperformed by 24.57% the S&P500.

Fibrogen Incorporated (NASDAQ:FGEN) had a decrease of 16.05% in short interest. FGEN’s SI was 2.16 million shares in November as released by FINRA. Its down 16.05% from 2.58M shares previously. With 462,100 avg volume, 5 days are for Fibrogen Incorporated (NASDAQ:FGEN)’s short sellers to cover FGEN’s short positions. The SI to Fibrogen Incorporated’s float is 3.96%. About 120,185 shares traded. FibroGen Inc (NASDAQ:FGEN) has risen 52.86% since November 14, 2016 and is uptrending. It has outperformed by 36.16% the S&P500.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 16 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of FibroGen Inc (NASDAQ:FGEN) earned “Buy” rating by Jefferies on Monday, August 14. Lake Street initiated it with “Hold” rating and $25 target in Wednesday, September 23 report. As per Wednesday, July 29, the company rating was initiated by Citigroup. The firm has “Neutral” rating given on Friday, July 21 by Goldman Sachs. Jefferies maintained FibroGen Inc (NASDAQ:FGEN) on Tuesday, August 8 with “Buy” rating. The rating was initiated by Citigroup on Friday, December 4 with “Buy”. The stock has “Neutral” rating by Credit Suisse on Thursday, January 21. The firm earned “Hold” rating on Wednesday, October 4 by Mizuho. The stock of FibroGen Inc (NASDAQ:FGEN) earned “Buy” rating by Stifel Nicolaus on Wednesday, October 18. Credit Suisse upgraded it to “Outperform” rating and $40 target in Thursday, February 11 report.

FibroGen, Inc. is a science-based biopharmaceutical firm discovering and developing a pipeline of first- in-class therapeutics. The company has market cap of $3.63 billion. The Firm is focused on fibrosis and hypoxia-inducible factor biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. It currently has negative earnings. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS).

Afam Capital Inc decreased Ishares Msci Australia Index (EWA) stake by 35,515 shares to 124,855 valued at $2.71 million in 2017Q2. It also reduced Ishares Msci Netherlands Inves (EWN) stake by 34,962 shares and now owns 56,950 shares. Ishares Msci Austria Index (EWO) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :